125,807 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Purchased by Equitable Trust Co.

Equitable Trust Co. acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 125,807 shares of the company’s stock, valued at approximately $1,524,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. JPMorgan Chase & Co. grew its position in Elanco Animal Health by 76.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock valued at $147,747,000 after acquiring an additional 4,361,799 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Elanco Animal Health in the 3rd quarter valued at about $19,708,000. Assenagon Asset Management S.A. grew its position in Elanco Animal Health by 363.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,548,506 shares of the company’s stock valued at $22,748,000 after acquiring an additional 1,214,123 shares in the last quarter. Private Management Group Inc. grew its position in Elanco Animal Health by 63.4% in the 4th quarter. Private Management Group Inc. now owns 2,357,142 shares of the company’s stock valued at $28,545,000 after acquiring an additional 914,808 shares in the last quarter. Finally, Point72 DIFC Ltd acquired a new position in Elanco Animal Health in the 3rd quarter valued at about $9,969,000. 97.48% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Morgan Stanley decreased their price objective on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 29th. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. UBS Group assumed coverage on Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 price objective for the company. Leerink Partners assumed coverage on Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective for the company. Finally, Stifel Nicolaus decreased their price objective on Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $16.29.

Elanco Animal Health Price Performance

ELAN stock opened at $11.47 on Tuesday. The business has a 50 day moving average price of $12.01 and a 200 day moving average price of $13.19. The stock has a market cap of $5.67 billion, a price-to-earnings ratio of 28.67, a PEG ratio of 2.69 and a beta of 1.42. Elanco Animal Health Incorporated has a fifty-two week low of $11.11 and a fifty-two week high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.